skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Introduction

Around 330,000 patients with mild cognitive impairment or mild to moderate Alzheimer’s disease will receive immunotherapies annually by 2021, allowing the treatment of this disease to reach an entirely new audience. This is just one catalyst contributing to the market value doubling in size over 2012-21. Datamonitor Healthcare has used a patient based approach to size the commercial potential of Alzheimer’s disease across the US, Japan and five major EU market. 

How will our Alzheimer’s disease forecast report benefit you?

  • Gain competitive insight
    Access an in-depth patient based report that details individual drugs in each disease setting via sales values and patient value, allowing you to assess your product positioning against those with the highest commercial value.
  • Prepare for market change
    Understand how the growing treated population within the Alzheimer’s market will change due to a shift in the diagnosing timeline over the forecast period to establish where you should be targeting new product developments.
  • Benchmark your product
    Understand how two new emerging product classes, 5-HT6 receptor antagonists and alpha-7 nAChR agonists, will compete against and complement existing market products, to help benchmark your product against new emerging classes and identify where your product will fit within the new market.
  • Identify investment opportunities
    See how potential disease modifying therapies, such as solanezumab the one pipeline drug suited to treat early stage patients, perform in various stages of Alzheimer’s disease, to help you identify any unmet needs within the early stages of the disease.

Key questions answered

  • How does the value of treating each stage of Alzheimer’s disease progress over the next decade and which factors are contributing to this?
  • How will Pfizer/Eisai’s Aricept, formerly the highest selling brand in the market, perform with the emergence of generic competition?
  • Which developmental products will emerge from the pipeline and what are their commercial potentials?
  • How does the Alzheimer’s disease market differ in each major region and which events will influence their future direction?

Read also

  • Datamonitor Healthcare: data analysis and insight

    mHealth and Research in Oncology

    The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit. 

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    Gene therapy manufacturers

    Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

  • Biomedtracker: see the drug development process through anal...

    Deconstructing the KRAS+ market opportunity

    By Daniel Chancellor

    With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target

    Topics BioPharmaceutical Drug Review

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: